Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.003 | 0 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.8184 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.